8-K: Immunovant Announces Positive Phase 3 Results for Batoclimab in Myasthenia Gravis and Phase 2b Results in Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant reports positive topline results from its Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial results from Period 1 of its Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), demonstrating significant clinical improvements.

Summary

• Immunovant's Phase 3 study of batoclimab in MG met its primary endpoint, showing a 5.6 point improvement in MG-ADL score in the higher dose arm (680mg weekly) and a 4.7 point improvement in the lower dose arm (340mg weekly) at 12 weeks in AChR+ participants.
• The higher dose arm achieved a 74% mean IgG reduction, while the lower dose arm achieved a 64% mean IgG reduction.
• Initial results from Period 1 of the Phase 2b study in CIDP demonstrated a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms.
• In the CIDP study, an 84% responder rate was observed in patients who achieved an IgG lowering greater than 70%.
• Deeper IgG reductions correlated with better clinical outcomes in both MG and CIDP studies.
• Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402.
• The company does not intend to seek regulatory approval for batoclimab in MG or CIDP at present, focusing on IMVT-1402.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for Immunovant's drug candidates. The focus on IMVT-1402 as a potentially best-in-class therapy further boosts the positive sentiment.

Positives

• The Phase 3 MG study met its primary endpoint, demonstrating significant improvement in MG-ADL scores.
• Deeper IgG reductions correlated with better clinical outcomes in both MG and CIDP studies.
• The company has active INDs for both MG and CIDP with IMVT-1402, paving the way for pivotal study initiations.
• Initial CIDP results show a meaningful improvement in disability scores and a high responder rate with significant IgG reduction.
• Batoclimab 680mg demonstrates the best-in-class MG-ADL response rate, raising the ceiling of therapeutic effect observed with any FcRn.
• Batoclimab 680mg outperforms other FcRns in achieving deep response rates in MG patients across Phase 3 programs.

Negatives

• Immunovant does not intend to seek regulatory approval for batoclimab in MG or CIDP at present, which may disappoint some investors.
• The Phase 2b CIDP study is ongoing, and the primary endpoint data from Period 2 is not yet available.

Risks

• The development and regulatory approval of IMVT-1402 are subject to risks and uncertainties.
• Clinical trials may not confirm the safety, potency, or other product characteristics described.
• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of IMVT-1402.
• Immunovant will require additional capital to fund its operations and advance IMVT-1402 through clinical development.

Future Outlook

Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402 and will wait to make a final decision about regulatory submissions for batoclimab until the results of the ongoing Phase 3 studies of batoclimab in thyroid eye disease are available.

Management Comments

• Pete Salzmann, M.D., chief executive officer of Immunovant, stated that deeper IgG reduction leads to deeper responses in MG and CIDP.
• Pete Salzmann believes that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, will apply to a wide range of auto-antibody mediated conditions.

Industry Context

The announcement highlights Immunovant's progress in the competitive field of FcRn inhibitors for autoimmune diseases, where companies are striving to achieve deeper and more durable clinical responses. The results position IMVT-1402 as a potentially best-in-class therapy.

Comparison to Industry Standards

• The 680mg batoclimab dose demonstrated the greatest change from baseline to primary endpoint in MG-ADL observed across any mechanism in a Phase 3 MG trial.
• The results are compared to Vyvgart (efgartigimod) and Nipocalimab in terms of MG-ADL reduction and responder rates.
• Batoclimab 680mg demonstrates the best-in-class MG-ADL response rate, raising the ceiling of therapeutic effect observed with any FcRn.
• Batoclimab 680mg outperforms other FcRns in achieving deep response rates in MG patients across Phase 3 programs.
• Batoclimab treated patients achieved a best-in-class mean change from baseline in aINCAT score at Week 12 compared to Vyvgart Hytrulo in CIDP patients.
• Batoclimab achieves deeper therapeutic effect than Vyvgart Hytrulo in CIDP patients across multiple efficacy endpoints at Week 12.

Stakeholder Impact

• The positive results could lead to increased shareholder value.
• Patients with MG and CIDP may benefit from new and improved treatment options.
• The company's employees may experience increased job security and growth opportunities.

Next Steps

• Immunovant plans to initiate potentially registrational studies in both MG and CIDP with lead asset IMVT-1402.
• The company will await results from the Phase 3 studies of batoclimab in thyroid eye disease before making a final decision about regulatory submissions for batoclimab.

Key Dates